Full Text View
Tabular View
No Study Results Posted
Related Studies
Vitamin Replacement in Abetalipoproteinemia
This study has been completed.
First Received: February 17, 2000   Last Updated: March 3, 2008   History of Changes
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00004574
  Purpose

This study will determine whether short term intravenous infusion of vitamins A and E in patients with abetalipoproteinemia can reverse disease symptoms in these patients. Abetalipoproteinemia is an inherited metabolic defect that prevents fat-soluble vitamins, such as A and E, from being absorbed from the intestines into the bloodstream and from being secreted by the liver. The deficiencies of vitamins A and E can result in severe vision impairment and a gait disorder. Treatment with megadoses of these vitamins, taken by mouth, may delay or arrest symptoms, but many continue to progress.

For this study, a single patient with moderately severe eye and neurological defects will be given essential fatty acids and fat soluble vitamins directly through a vein (intravenously) using FDA-approved replacements with a fat emulsion and multivitamins containing fat-soluble vitamins. This route of administration will bypass the digestive tract, where the absorption problem occurs. The infusions will be given twice a week for one month and then weekly for another month. Blood tests will be done weekly to measure blood lipids (fatty acids and other substances), cell counts, and vitamin levels. Eye and neurological examinations will be done once a month.


Condition
Abetalipoproteinemia

Genetics Home Reference related topics: abetalipoproteinemia Chanarin-Dorfman syndrome cholesteryl ester storage disease Farber lipogranulomatosis Friedreich ataxia long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency mitochondrial trifunctional protein deficiency primary carnitine deficiency Tangier disease
U.S. FDA Resources
Study Type: Observational
Official Title: Vitamin Replacement in Abetalipoproteinemia

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 1
Study Start Date: February 2000
Estimated Study Completion Date: May 2001
Detailed Description:

Fat-soluble vitamins are normally absorbed from the diet through the gastrointestinal tract and incorporated into fat-rich particles called chylomicrons made in the intestinal wall. Chylomicrons are secreted by the intestine into the bloodstream. In a rare lipid metabolic disorder called abetalipoproteinemia, a defect in the assembly of the fat and vitamin containing particles prevents the formation of chylomicrons resulting in the malabsorption of fat and fat-soluble vitamins. A similar assembly defect of fat and fat-soluble vitamins occurs in the liver and prevents the secretion of these particles. Severe fat-soluble vitamin deficiency results even despite mega doses of oral fat-soluble vitamins. Clinically, the subjects develop neurologic and ophthalmologic symptoms similar to those in Vitamin A and E deficiency. This study is designed to determine whether short-term intravenous fat-soluble vitamins and fat emulsion can reverse the neurologic and ophthalmologic complications of fat-soluble vitamin deficiency based on noninvasive procedures routinely employed in clinical practice.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

None provided - protocol is intended for one patient only.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004574

Locations
United States, Maryland
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
Study ID Numbers: 000076, 00-H-0076
Study First Received: February 17, 2000
Last Updated: March 3, 2008
ClinicalTrials.gov Identifier: NCT00004574     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Abetalipoproteinemia
Ataxia
Retinitis Pigmentosa
Vitamin A
Vitamin E

Study placed in the following topic categories:
Lipid Metabolism, Inborn Errors
Retinitis
Hypolipoproteinemias
Hypolipoproteinemia
Abetalipoproteinemia
Hypobetalipoproteinemias
Pigmentary Retinopathy
Tocopherols
Metabolism, Inborn Errors
Acanthocytosis
Retinol palmitate
Vitamins
Retinitis Pigmentosa
Ataxia
Tocotrienols
Micronutrients
Metabolic Disorder
Dyslipidemias
Tocopherol acetate
Metabolic Diseases
Trace Elements
Alpha-Tocopherol
Cone Rod Dystrophy
Vitamin E
Genetic Diseases, Inborn
Vitamin A
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Growth Substances
Physiological Effects of Drugs
Hypolipoproteinemias
Pharmacologic Actions
Abetalipoproteinemia
Hypobetalipoproteinemias
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Vitamins
Micronutrients
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on May 07, 2009